G-四链体在抗肿瘤药物和神经退行性疾病方面的研究进展

摘要/Abstract

摘要： 转化医学是近年来医学领域中出现的一个新概念,旨在在基础研究和临床医疗之间建立更紧密的联系.富含鸟嘌呤(G)核苷酸序列形成的稳定G-四链体与人类重大疾病如肿瘤、神经退行性疾病密切相关,已成为转化医学研究中的一个重要方向.在端粒序列,G-四链体的形成和稳定可以抑制端粒酶活性,因此研发能稳定G-四链体结构的配体对抗肿瘤药物开发具有重大意义.此外,近年来神经退行性疾病中G-四链体的研究也取得重要进展.对与G-四链体相关的抗肿瘤药物研发和神经退行性疾病研究进行简要的总结.

关键词: G-四链体, 小分子配体, 抗肿瘤药物, 神经退行性疾病

Abstract: In the last decade, translational medicine came into the limelight, aiming to bridge the gap between basic research and clinical application. The association of G-quadruplex with life-threating and debilitating diseases is an emerging topic in translational medicine. Since the formation of G-quadruplex can inhibit telomerase activity, the ligands that can stabilize G-quadruplex have great significance for cancer therapeutics. In addition, growing evidence suggests the implication of quadruplex in neurodegenerative diseases. In this review, the research of G-quadruplex in the fields of anti-tumor drugs and neurodegenerative diseases is discussed.

Key words: G-quadruplex, small molecule ligands, anti-tumor drugs, neurodegenerative diseases

中图分类号:

R361

卢会茹,,高愈希,张金超,胡毅. G-四链体在抗肿瘤药物和神经退行性疾病方面的研究进展[J]. 医学研究与教育, 2013, 30(2): 1-7.

参考文献

[1] 凌宝存. 转化医学的研究及发展 [J]. 实用医药杂志 2012.doi:10.3969/j.issn.1671-4008.2012.01.060
[2] Declan Butler. Crossing the valley of death [J]. Nature 2008, 7197(7197).
[3] Heddi, B., Phan, A.T.. [J]. Journal of the American Chemical Society 2011.
[4] Neidle S, Harrison RJ, Reszka AP, Read MA. [J]. Pharmacology and Therapeutics: The Journal of the International Encyclopedia of Pharmacology and Therapeutics 2000.
[5] ZAHLER A M, WILLIAMSON J R, CECH T R. Inhibition of telomerase by G-quartet DNA structures [J]. NATURE 1991, 350(6320).
[6] Perry PJ, Gowan SM, Reszka AP, Polucci P, Jenkins TC, Kelland LR, Neidle S. [J]. Journal of Medicinal Chemistry 1998.
[7] Perry PJ, Reszka AP, Wood AA, Read MA, Gowan SM, Dosanjh HS, Trent JO, Jenkins TC, Kelland LR, Neidle S. [J]. Journal of Medicinal Chemistry 1998.
[8] Harrison RJ, Gowan SM, Kelland LR, Neidle S. [J]. Bioorganic and Medicinal Chemistry Letters 1999.
[9] Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, Kelland LR. [J]. Molecular pharmacology 2002.
[10] R. John Harrison, Javier Cuesta, Gianni Chessari, Martin A. Read, Sanji K. Basra, Anthony P. Reszka, James Morrell, Sharon M. Gowan, Christopher M. Incles, Farial A. Tanious. [J]. Journal of Medicinal Chemistry 2003.
[11] Harrison RJ, Reszka AP, Haider SM, Romagnoli B, Morrell J, Read MA, Gowan SM, Incles CM, Kelland LR, Neidle S. [J]. Bioorganic and Medicinal Chemistry Letters 2004.
[12] Schultes CM, Guyen B, Cuesta J, Neidle S. [J]. Bioorganic and Medicinal Chemistry Letters 2004.
[13] Michael J.B.Moore, Christoph M.Schultes, Javier Cuesta, Francisco Cuenca, Mekala Gunaratnam. [J]. Journal of Medicinal Chemistry 2006.
[14] Kazuo Shin-ya, Konstanty Wierzba, Ken-ichi Matsuo. Telomestatin, a Novel Telomerase Inhibitor from Streptomyces anulatus [J]. Journal of the American Chemical Society 2001, 6(6).
[15] KIM M Y, VANKAYALAPATI H, SHIN-YA K. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex [J]. Journal of the American Chemical Society 2002, 124(10).
[16] WANG Y, PATEL D J. Guanine residues in d(T2AG3) and d(T2G4) form parallel-stranded potassium cation stabilized G-quadruplexes with antiglycosidic torsion angles in solution [J]. Biochemistry 1992, 31(35).
[17] ANANTHA N V, AZAM M, SHEARDY R D. Porphyrin binding to quadruplexed T4G4 [J]. Biochemistry 1998, 37(09).
[18] Wheelhouse RT., Han HY., Han FXG., Hurley LH., Sun DK.. Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(N-methyl-4-pyridyl)porphine with quadruplex DNA [J]. Journal of the American Chemical Society 1998, 13(13).
[19] Evans SE, Mendez MA, Turner KB, Keating LR, Grimes RT, Melchoir S, Szalai VA. [J]. Journal of biological inorganic chemistry: JBIC: a publication of the Society of Biological Inorganic Chemistry 2007.
[20] Alexandrine Maraval, Sonia Franco, Corine Vialas, Genevieve Pratviel, Maria A. Blasco, Bernard Meunier. [J]. Organic & biomolecular chemistry 2003.
[21] Dixon IM, Lopez F, Esteve JP, Tejera AM, Blasco MA, Pratviel G, Meunier B. [J]. Chembiochem: A European journal of chemical biology 2005.
[22] Dixon IM, Lopez F, Tejera AM, Esteve JP, Blasco MA, Pratviel G, Meunier B. [J]. Journal of the American Chemical Society 2007.
[23] Fedoroff OY., Han HY., Chemeris VV., Kerwin SM., Hurley LH., Salazar M.. [J]. Biochemistry 1998.
[24] GUO Q, LU M, MARKY L A. Interaction of the dye ethidium bromide with DNA containing guanine repeats [J]. Biochemistry 1992, 31(09).
[25] Koeppel F, Riou JF, Laoui A, Mailliet P, Arimondo PB, Labit D. [J]. Nucleic Acids Research 2001.
[26] Franceschin M, Rossetti L, D'Ambrosio A, Schirripa S, Bianco A, Ortaggi G, Savino M, Schultes C, Neidle S. [J]. Bioorganic and Medicinal Chemistry Letters 2006.
[27] Bhadra K, Kumar GS. [J]. Biochimica et Biophysica Acta. General Subjects 2011.
[28] Zhang WJ, Ou TM, Lu YJ, Huang YY, Wu WB, Huang ZS, Zhou JL, Wong KY, Gu LQ. 9-Substituted berberine derivatives as G-quadruplex stabilizing ligands in telomeric DNA. [J]. Bioorganic and medicinal chemistry 2007, 16(16).
[29] PEARSON C E, SINDEN R R. Trinucleotide repeat DNA structures:dynamic mutations from dynamic DNA [J]. Current Opinion in structural Biology 1998, 8(03).
[30] Yerkes S, Vesenka J, Kmiec EB. A stable G-quartet binds to a huntingtin protein fragment containing expanded polyglutamine tracks. [J]. Journal of Neuroscience Research 2010, 2(2).
[31] Jean-Fran?ois Fisette, Daniel R Montagna, Mihaela-Rita Mihailescu, Michael S Wolfe. A G-rich element forms a G-quadruplex and regulates BACE1 mRNA alternative splicing. [J]. Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry 2012, 5/6(5/6).
[32] YU S, PRITCHARD M, KREMER E. Fragile X genotype characterized by an unstable region of DNA [J]. SCIENCE 1991, 252(5010).
[33] FU Y, KUHL D P, PIZZUTI A. Variation of the CGG repeat at the fragile X site results in genetic instability:Resolution of the Sherman paradox [J]. CELL 1991, 67(06).
[34] CHOWDHURY S, BANSAL M. Modelling studies on neurodegenerative disease-causing triplet repeat sequences d(GGC/GCC)n and d(CAG/CTG)n [J]. Journal of Biosciences 2001, 26(05).
[35] FRY M, LOEB L A. The fragile X syndrome d(CGG)n nucleotide repeats form a stable tetrahelical structure [J]. Proceedings of the National Academy of Sciences(USA) 1994, 91(11).
[36] Kettani A, Kumar RA, Patel DJ. [J]. Journal of Molecular Biology 1995.
[37] Di Prospero NA, Fischbeck KH. Therapeutics development for triplet repeat expansion diseases. [J]. Nature reviews. Genetics 2005, 10(10).
[38] WELLS R D. Mutation spectra in fragile X syndrome induced by deletions of CGG*CCG repeats [J]. Journal of Biological Chemistry 2009, 284(12).
[39] LEE S W, SONG M K, BAEK K H. Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxy-nucleotides on their immunostimulatory potentials [J]. Journal of Immunology 2000, 165(07).
[40] DALPKE A H, ZIMMERMANN S, ALBRECHT I. Phosphodiester CpG oligonucleotides as adjuvants:polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo [J]. IMMUNOLOGY 2002, 106(01).
[41] JULIANO R L, YOO H. Aspects of the transport and delivery of antisense oligonucleotides [J]. Current Opinion in Molecular Therapeutics 2000, 2(03).
[42] BIESSEN E A, VIETSCH H, KUIPER J. Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors [J]. Molecular Pharmacology 1998, 53(02).
[43] Kaur H, Jaso-Friedmann L, Evans DL. [J]. Fish & Shellfish Immunology 2003.
[44] PAPADOPOULOS K, MITA A, RICART A. Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543):A protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors [J]. Molecular Cancer Therapautics 2007, 6(12).
[45] LABER D A, TAFT B S, KLOECKER G H. Pharmacokinetics of the anti-nucleolin aptamer AS1411 in a phase I study [J]. Molecular Cancer Therapautics 2007, 6(12).